Posts

Posted on

SHAREHOLDER ALERT: WeissLaw LLP Investigates Vesper Healthcare Acquisition Corp.

PR Newswire

NEW YORK, Dec. 10, 2020 /PRNewswire/ — WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Vesper Healthcare Acquisition Corp. (“Vesper” or the “Company”) (NASDAQ: VSPR) in connection with the Company’s proposed merger with The HydraFacial Company (“HydraFacial”), a privately-held category-creating beauty health company.  Under the terms of the merger agreement, Vesper will acquire HydraFacial through a reverse merger that will result in HydraFacial becoming a public company traded on the NASDAQ exchange.  The transaction values HydraFacial at an enterprise value of approximately $1.1 billion.


If you own Vesper shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

https://www.weisslawllp.com/VSPR/


Or please contact:


Joshua Rubin, Esq.

WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

WeissLaw is investigating whether Vesper’s board acted in the best interest of Vesper’s public shareholders in agreeing to the proposed transaction, whether the board was fully informed as to the valuation of HydraFacial, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Vesper public shareholders. 

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-vesper-healthcare-acquisition-corp-301190060.html

SOURCE WeissLaw LLP

Posted on

Pure Extracts Preparing Application for Dealers Licence

VANCOUVER, British Columbia, Dec. 10, 2020 (GLOBE NEWSWIRE) — Pure Extracts Technologies Corp. (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp and the rapidly emerging functional mushroom sector, is pleased to announce that it has engaged a globally recognized operations, compliance, and regulatory consulting firm to advise on the Company’s application to Health Canada for a Dealers Licence under the Controlled Drugs and Substances Act (CDSA).

The CDSA and its Regulations provide, among other things, the framework for legal access to controlled substances, and the control and regulation of production, distribution, and sale. One of Health Canada’s responsibilities is to provide the licensing and oversight framework for the legal production of controlled substances.

Under this framework, a company is required to obtain a licence issued by Health Canada in order to conduct various activities with controlled substances. Licence holders are responsible for compliance with the CDSA and its Regulations as well as compliance with other applicable federal, provincial, and territorial legislation and municipal by-laws. The issued licence dictates activities, conditions, and restrictions for the licence holder depending on licence permissions.

A Dealer’s Licence could allow for the following activities:

  • Procurement of controlled substances, including by import, synthesis, propagation, cultivation and harvesting of psychedelic mushrooms for psilocybin extraction
  • Research and manufacture of controlled substances such as psilocybin and psilocin
  • Business to business sale of controlled substances, including by export
  • Sale of controlled substance via pharmacies

Pure Extracts CEO, Ben Nikolaevsky, remarked, “Having the support of one of Canada’s premiere consulting companies with subject matter proficiency in cannabis and other regulated consumer product industries assures that we will submit a fully-compliant Dealers Licence application to Health Canada in the shortest time possible. As a plant-based extractor bringing functional mushroom products to market in Q1 2021, we are very excited to be laying the groundwork for our move into the controlled substances world of psychedelics.”

Having the ability to do extraction research and development into psychedelic compounds such as psilocybin and psilocin will prepare Pure Extracts to work with partners such as medical doctors, pharmaceutical company and pharmacies as clinical trials lead to the legalization of psychedelics and the advancement of micro-dosing in the near future.

Submission of the Company’s Dealer’s Licence application is subject to compliance with applicable securities laws, including any necessary approvals by the CSE.

The Company also announces that it has entered into an agreement with Market IQ Media Group on a month-to-month basis for marketing, communication, shareholder engagement and social media communication. The marketing and communication program will include certain investor relations activities and is designed to provide improved visibility in the Company’s current and planned operations.


About Pure Extracts

(
CSE: PULL
)
(XFRA: A2QJAJ)

The Company features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act and the Company’s stock began trading on the Canadian Securities Exchange (CSE) on November 5, 2020. Find out more at https://pureextractscorp.com/.

For further information please contact Empire Communications Group at (604) 343-2724.

ON BEHALF OF THE BOARD

“

Ben Nikolaevsky

”

Ben Nikolaevsky
CEO and Director

The CSE has neither approved nor disapproved the contents of this press release.

This news release contains forward-looking statements relating to the future operations of Pure Extracts, and the other statements are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. The Company is in the preliminary stages of preparing a Dealer’s License application and there is no certainty on the timing of such application, or that the Company will ultimately be successful is obtaining a Dealer’s License. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of Pure Extracts’, are forward-looking statements and involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of Pure Extracts include risks detailed from time to time in the filings made by Pure Extracts under securities regulations.

 



Posted on

JinkoSolar Announces Update to 2020 Annual General Meeting Agenda

PR Newswire

SHANGRAO, China, Dec. 10, 2020 /PRNewswire/ — JinkoSolar Holding Co., Ltd. (“JinkoSolar” or the “Company”) (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that it updates the agenda of its 2020 annual general meeting announced on November 26, 2020, by adding the following ordinary resolution:

  • That the appointment of Mr. Haiyun (Charlie) Cao as a director be ratified and that he be re-elected as a director of the Company.

The updated notice of the Company’s annual general meeting is available on the Investor Relations Section of the Company’s website at www.jinkosolar.com.

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and other countries and regions. JinkoSolar has built a vertically integrated solar product value chain, with an integrated annual capacity of 20 GW for mono wafers, 11 GW for solar cells, and 25 GW for solar modules, as of September 30, 2020.

JinkoSolar has 9 productions facilities globally, 21 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, United States, Mexico, Brazil, Chile, Australia, Portugal, Canada, Malaysia, UAE, Kenya, Hong Kong, Denmark, and global sales teams in China, United Kingdom, France, Spain, Bulgaria, Greece, Ukraine, Jordan, Saudi Arabia, Tunisia, Morocco, Kenya, South Africa, Costa Rica, Colombia, Panama, Kazakhstan, Malaysia, Myanmar, Sri Lanka, Thailand, Vietnam, Poland and Argentina, as of September 30, 2020.

To find out more, please see: www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends, “plans,” “believes,” “estimates” and similar statements. Among other things, the quotations from management in this press release and the Company’s operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

In China:
Ripple Zhang
JinkoSolar Holding Co., Ltd.
Tel: +86 21-5183-3105
Email: [email protected]

Rene Vanguestaine
Christensen
Tel: + 86 178 1749 0483
Email: [email protected]  

In the U.S.:
Ms. Linda Bergkamp
Christensen
Tel: +1-480-614-3004
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/jinkosolar-announces-update-to-2020-annual-general-meeting-agenda-301190040.html

SOURCE JinkoSolar Holding Co., Ltd.

Posted on

New Whirlpool Corporation research uncovers shift in life at home during 2020; expert predicts changes are here to stay

PR Newswire

BENTON HARBOR, Mich., Dec. 10, 2020 /PRNewswire/ — With 2020 drawing to a close, many are speculating about when life will return to normal. But experts say COVID-19 has forever changed the world already–including life at home. To understand how the pandemic will impact life at home in the long-term, home appliance manufacturer Whirlpool Corporation has commissioned new research to understand how lives have changed in 2020.

The report has found that more than half of U.S. adults (53 percent) surveyed are spending on average an extra 7.4 hours at home each day, equating to over two extra days at home per week.* This has created positive shifts in dynamics in households–which experts predict could remain for the long-term.

The research, conducted with YouGov among adults in the U.S., found:

A shift in household responsibilities

  • 14 percent of those surveyed are cooking together more as a household since the pandemic began, allowing the inference that nearly 36 million people in the U.S. are cooking together more.
  • For 12 percent housework has also become more of a joint effort than ever before, meaning that over 15 million households in the U.S. are sharing more chores–with laundry (66 percent) and cooking (65 percent) the most popular shared chores among those sharing the effort.

More quality time spent together as a household

  • Nearly a quarter (24 percent) say they feel closer to friends and family.
  • Unsurprisingly, the most popular reason for this is people spending more time as a household (57 percent). But also one in five (22 percent) say it’s because they have been exercising or learning new skills together.

Finding time for self-improvement

  • More people have become hobbyists. 16 percent (which would represent nearly 41 million people in the U.S.) have taken up at least one new hobby or skill since the start of the pandemic.
  • From the given list, cooking (29 percent), gardening (23 percent), drawing/painting (23 percent) and embarking on a new course of learning (21 percent) are the most popular hobbies picked up by those who have started a new one.
  • 17 percent also say they’ve become more creative in the kitchen.

Perhaps it’s no surprise that nearly a third (32 percent) say they’ve found a new appreciation for their homes this year, and 27 percent say spending more time at home has produced unexpected positives.

It’s not likely to change either. Although half of people (54 percent) hope life returns to normal heading into 2021, over a quarter (28 percent) say they want to keep up the positive new changes they’ve made at home long-term.

“When the world feels chaotic, we often look for shelter and comfort in our homes as somewhere we can control. That’s never been more true than over the last few months,” says Meik Wiking, world-leading happiness expert, New York Times bestselling author and CEO, The Happiness Research Institute. “As this study shows, the effort we’ve made to make our homes a sanctuary from the outside world has led to us making changes to our home lives and household dynamics. From transforming what our homes look like, to reviewing how we share the housework, to thinking about how we can continue to grow as individuals—even if it’s within our four walls. Looking ahead to 2021, we might not be able to keep up all the good hobbies we’ve picked up, but I think the understanding that happiness is homemade is here to stay.”

The Improving Life At Home online hub
To help people keep these habits up, Whirlpool Corporation is launching a new “Improving Life At Home” online hub, which brings expert advice together from across its many brands, with tips from happiness expert Wiking: http://www.improvinglifeathome.com/.

“At Whirlpool Corporation, we are in constant pursuit of improving life in the home,” said Eleanor Reece, senior director of global campaigns, Whirlpool Corporation. “That’s why we commissioned this new study to understand how lives have changed in the last year. Amidst the hardships, challenges and uncertainty that have come in 2020, it’s been heartening to see some silver linings as new dynamics and habits emerge in homes everywhere. We want to play our part in helping people keep those up, which is why we’ve launched this online hub, which brings together the best of our company’s advice-led content to help people make the most of life at home.”

About Whirlpool Corporation
Whirlpool Corporation (NYSE: WHR) is the world’s leading kitchen and laundry appliance company, with approximately $20 billion in annual sales, 77,000 employees and 59 manufacturing and technology research centers in 2019. The company markets Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, Indesit and other major brand names in nearly every country throughout the world. Additional information about the company can be found at whirlpoolcorp.com.

About Meik Wiking & The Happiness Research Institute

Meik Wiking is the CEO of The Happiness Research Institute and is a New York Times and The Times Bestselling author. His books, which have sold 2 million copies worldwide, include The Little Book of Hygge, The Little Book of Lykke, and The Art of Making Memories.

Besides his work at the Happiness Research Institute, he is Research Associate for Denmark at the World Database of Happiness, member of the policy advisory group for the Global Happiness Policy Report, Board Member at The Health and Happiness Research Foundation, and creator of the Happiness Museum in Copenhagen.

Meik has been called The Indiana Jones of Smiles and probably the World´s happiest man by The Times.

*All figures, unless otherwise stated, are from YouGov Plc.  Total sample size was 1380 adults. Fieldwork was undertaken between 10th – 12th November 2020.  The survey was carried out online. The figures have been weighted and are representative of all US adults (aged 18+).

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/new-whirlpool-corporation-research-uncovers-shift-in-life-at-home-during-2020-expert-predicts-changes-are-here-to-stay-301190033.html

SOURCE Whirlpool Corporation

Posted on

Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis 16,666,667 shares of common stock of the Company, at a price to the public of $4.50 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 14, 2020, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company also has granted to the underwriter a 30-day option to purchase up to an additional 2,495,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Oncternal, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter’s option to purchase additional common stock, are expected to be approximately $75.0 million. The Company intends to use the net proceeds from this offering for general corporate purposes, including expenses related to the clinical and preclinical development of cirmtuzumab and TK216, preclinical development of its ROR1 CAR-T program, and for working capital.

The shares of common stock are being offered by Oncternal pursuant to a “shelf” registration statement on Form S-3 (File No. 333-222268) previously filed with the Securities and Exchange Commission (the “SEC”) on December 22, 2017 and declared effective by the SEC on January 5, 2018. The offering of the shares of common stock is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the shares of common stock being offered has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. A final prospectus supplement and the accompanying prospectus relating to the shares of common stock being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes , an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes , an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at .

Forward-Looking Information

Oncternal cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Oncternal’s current beliefs and expectations. Forward-looking statements include statements regarding: the completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of net proceeds from the offering. The inclusion of forward-looking statements should not be regarded as a representation by Oncternal that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Oncternal’s business, including, without limitation: market and other conditions and the satisfaction of customary closing conditions related to the offering; and other risks described in Oncternal’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Oncternal undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Oncternal Contacts:

Company Contact

Richard Vincent
858-434-1113
[email protected]

Investor
Contact

Corey Davis, Ph.D.         
LifeSci Advisors         
212-915-2577                 
[email protected]

Source: Oncternal Therapeutics, Inc.



Posted on

Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock

Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock

NEW YORK–(BUSINESS WIRE)–
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the pricing of an upsized underwritten public offering of 4,642,858 shares of its common stock at a public offering price of $56.00 per share. The gross proceeds to Rocket from the offering are expected to be approximately $260 million, before deducting the underwriting discounts and commissions and other offering expenses. Rocket has granted the underwriters a 30-day option to purchase up to an additional 696,428 shares of its common stock.

All the shares in the offering are to be sold by Rocket. The offering is expected to close on or about December 14, 2020, subject to satisfaction of customary closing conditions. Rocket intends to use the net proceeds from this offering to further fund the development of its pipeline of gene therapies for rare diseases, including filing for marketing authorization for RP-L201 in the United States and Europe, accelerating the buildout of in-house manufacturing capabilities, and for general corporate purposes. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler are acting as the joint bookrunning managers for the public offering.

The public offering is being made by Rocket pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (the “SEC”) and declared effective by the SEC. A final prospectus supplement relating to and describing the terms of this offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to these securities may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at [email protected], from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6132, or by email at [email protected], or from Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at [email protected]. You may also obtain these documents free of charge by visiting the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rocket Pharmaceuticals, Inc.

Rocket is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The company’s platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition.

Forward-looking Statements

Various statements in this release concerning Rocket’s future expectations, plans and prospects, including without limitation, Rocket’s expectations regarding the consummation of the offering, the satisfaction of customary closing conditions with respect to the offering, the anticipated use of the net proceeds of the offering, Rocket’s expectations regarding its guidance for 2020 in light of COVID-19, the safety, effectiveness and timing of product candidates that Rocket may develop to treat FA, LAD-I, PKD, IMO and Danon Disease and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “target,” “will,” “will give,” “would,” or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, changes as a result of market conditions or for other reasons, the risk that the offering will not be consummated, the impact of general economic, industrial or political conditions in the United States or internationally, Rocket’s ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of its patients, families and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket’s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled “Risk Factors” in Rocket’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed November 6, 2020. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Claudine Prowse, Ph.D.

SVP, Strategy & Corporate Development

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Health Stem Cells Genetics Pharmaceutical Cardiology Biotechnology

MEDIA:

Posted on

HSBC Holdings plc Announces a Proposed Offering of Additional Tier 1 Securities to Finance the Redemption of Its US Dollar Preference Shares

HSBC Holdings plc Announces a Proposed Offering of Additional Tier 1 Securities to Finance the Redemption of Its US Dollar Preference Shares

LONDON–(BUSINESS WIRE)–
HSBC Holdings plc (the ‘Company’, ‘we’ or ‘us’) announces the potential launch of an offering (the ‘Offering’) of a series of US dollar-denominated perpetual subordinated contingent convertible securities (the ‘Securities’), subject to market conditions.

Subject to the successful pricing of the Offering of the Securities (which is expected to occur on 10 December 2020, subject to market conditions), the Company intends to exercise its right to redeem all of its 1,450,000 6.20% Non-Cumulative Dollar Preference Shares, Series A (the ‘Preference Shares’) represented by American Depositary Shares, Series A (the ‘ADSs’) at a redemption price of US$1,000 per Preference Share and US$25 per ADS, plus accrued and unpaid dividends for the then-current dividend period to the redemption date. The Company intends to use the net proceeds from the sale of the Securities to redeem the Preference Shares and the ADSs, in accordance with the terms and conditions of the Preference Shares and the ADSs. Any of the net proceeds in excess of the redemption amount will be used for general corporate purposes and to further strengthen the Company’s capital base pursuant to regulatory requirements.

The Company has retained HSBC Securities (USA) Inc. as Sole Structuring Adviser and Book-Running underwriter for the Offering.

…..

The Offering is being made pursuant to an effective shelf registration statement on Form F-3 filed with the Securities and Exchange Commission (the ‘SEC’). The Offering is being made solely by means of a prospectus supplement and accompanying prospectus (together, the ‘Prospectus’) which has been or will be filed with the SEC. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov or by writing or telephoning us at either of the following addresses:

Group Company Secretary

HSBC Holdings plc

8 Canada Square

London E14 5HQ

United Kingdom

Tel: +44 20 7991 8888

HSBC Holdings plc

c/o HSBC Bank USA, National Association

452 Fifth Avenue

New York, New York, 10018

Attn: Company Secretary

Tel: +1 212 525 5000

The distribution of this communication and other information referred to herein may be restricted by law and persons into whose possession this communication or such other information comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This communication does not constitute an offer to sell or a solicitation of an offer to buy the Securities, nor shall there be any sale of the Securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This communication shall not constitute a notice of redemption with respect to the Preference Shares and the ADSs. A notice will be published in due course, to the extent that the Company exercises its redemption option.

This communication, the Prospectus and any other documents or materials relating to the Offering are for distribution only to persons who (i) have professional experience in matters relating to investments and who fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the ‘Financial Promotion Order’), (ii) are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations etc.) of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as ‘relevant persons’). This communication, the Prospectus and any other documents or materials relating to the Offering are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication, the Prospectus and any other documents or materials relating to the Offering relate is available only to relevant persons and will be engaged in only with relevant persons.

The Securities are complex financial instruments and are not a suitable or appropriate investment for all investors. In some jurisdictions, regulatory authorities have adopted or published laws, regulations or guidance with respect to the offer or sale of securities such as the Securities to retail investors. In particular, in June 2015, the FCA published the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015, which set out certain rules and took effect from 1 October 2015 (the ‘PI Rules’). In addition, (i) on 1 January 2018, the provisions of Regulation (EU) No 1286/2014 (as amended, the ‘PRIIPs Regulation’) on key information documents for packaged retail and insurance-based investment products became directly applicable in all European Economic Area (‘EEA’) member states and the United Kingdom (‘UK’), and (ii) MiFID II was required to be implemented in EEA member states and the UK by 3 January 2018. Together, the PI Rules, the PRIIPs Regulation and MiFID II are referred to as the ‘Regulations’.

The Regulations set out various obligations in relation to (i) the manufacturing and distribution of financial instruments and (ii) the offering, sale and distribution of packaged retail and insurance-based investment products and certain contingent write-down or convertible securities, such as the Securities.

Potential investors should inform themselves of, and comply with, any applicable laws, regulations or regulatory guidance with respect to any resale of the Securities (or any beneficial interests therein) including the Regulations.

The Securities are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA or in the UK. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, ‘MiFID II’); or (ii) a customer within the meaning of Directive (EU) 2016/97, where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently, no key information document required by the PRIIPs Regulation for offering or selling the Securities or otherwise making them available to retail investors in the EEA or in the UK has been prepared and therefore offering or selling the Securities or otherwise making them available to any retail investor in the EEA or in the UK may be unlawful under the PRIIPs Regulation.

Solely for the purposes of its obligations pursuant to Sections 309B(1)(a) and 309B(1)(c) of the Securities and Futures Act (Chapter 289 of Singapore) (the ‘SFA’), the Company has determined, and hereby notifies all relevant persons (as defined in Section 309A of the SFA) that the Securities are ‘prescribed capital markets products’ (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018 of Singapore) and ‘Excluded Investment Products’ (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

…..

Cautionary Statement Regarding Forward-Looking Statements

In this communication the Company has made forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements may be identified by the use of terms such as ‘believes’, ‘expects’, ‘estimate’, ‘may’, ‘intends’, ‘plan’, ‘will’, ‘should’, ‘potential’, ‘reasonably possible’ or ‘anticipates’ or the negative thereof or similar expressions, or by discussions of strategy. We have based the forward-looking statements on current expectations and projections about future events. These forward-looking statements are subject to risks, uncertainties and assumptions about us, as described under ‘Risk Factors’ in the Prospectus. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, the forward-looking events discussed herein might not occur. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of their dates.

Note to editors:

HSBC Holdings plc

HSBC Holdings plc, the parent company of the HSBC Group, is headquartered in London. HSBC serves customers worldwide from offices in 64 countries and territories in our geographical regions: Europe, Asia, North America, Latin America, and Middle East and North Africa. With assets of US$2,956bn at 30 September 2020, HSBC is one of the world’s largest banking and financial services organisations.

Investor enquiries to:

Greg Case

+44 (0) 20 7992 3825

[email protected]

Media enquiries to:

Ankit Patel

+44 (0) 20 7991 9813

[email protected]

KEYWORDS: United Kingdom Europe

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo
Posted on

Stellar Results from Kintor’s GT90001 and Opdivo Combo Therapy in the Second-line Treatment of Advanced Liver Cancer: ORR Reached up to 40%

PR Newswire

SHANGHAI, Dec. 9, 2020 /PRNewswire/ — On December 9, 2020, Kintor Pharmaceutical Limited (HKEx: 9939) is pleased to announce that the Group has collected positive data in phase II clinical trials of combination therapy of ALK-1 (GT90001) antibody and PD-1 (Nivolumab or Opdivo) antibody for the second line therapy of advanced hepatocellular carcinoma (“HCC”) in Taiwan (the “Phase II Clinical Trial”). The preliminary data of the ongoing Phase II Clinical Trial showed positive efficacy and safety results. The data collected in the Phase II Clinical Trial will be released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) to be held between January 15-17, 2021.

  • Poster presentation

Abstract Title: 
Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC)
Abstract Number: 326
First Author: Chiun Hsu, MD

GT90001 is a fully humanised monoclonal antibody that inhibits ALK-1/TGF-β signal transduction and tumor angiogenesis and a potential first-in-class antibody for which we obtained an exclusive global license from Pfizer, Inc. in February 2018. The Phase II Clinical Trial was commenced on May 7, 2019 in Taiwan to evaluate the safety and efficacy of GT90001 in combination therapy with Nivolumab in patients with advanced HCC who were progressed on or intolerant to first line therapy with Sorafenib or Lenvatinib.

The Phase II Clinical Trial (NCT03893695) was a single-arm, open-ended and two-stage clinical trial. The Phase II Clinical Trial mainly observed the safety, tolerability and anti-tumor activity of the combination therapy of GT90001 and Nivolumab. In the first stage (safety evaluation cohort), six patients were enrolled in the dose group of 7mg/kg of GT90001 biweekly and 3mg/kg of Nivolumab biweekly. In the second stage (expanded cohort), 14 patients were enrolled at the same dose for combination therapy. According to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1, patients received treatment until experiencing disease progression or intolerable toxicity was developed. The primary efficacy endpoint was the objective response rate (ORR) assessed by the investigators.

From July 9, 2019 to September 30, 2020, among the 20 evaluable patients, eight patients (40.0%) were observed partial remission (PR). The side effects were well tolerated and manageable. The pharmacokinetic parameters of GT90001 and Nivolumab are similar to those of monotherapy.

Dr. Tong Youzhi, the founder, Chairman and CEO of Kintor Pharmaceutical, said, “Upon obtaining the exclusive global rights of GT90001, Kintor has implemented the development strategy to combine GT90001 with immunotherapy. GT90001, in combination with Nivolumab, has showed positive efficacy and safety results. We are actively initiating MRCT phase II/III clinical trials in China and US for the treatment of advanced HCC. Meanwhile, we are exploring innovative therapies for the treatment of other solid tumors.”

About GT90001

GT90001 is a fully human monoclonal antibody against ALK-1 (Activin Receptor-Like Kinase-1, Activin Receptor-Like Kinase-1). Kintor Pharmaceutical obtained the global exclusive development, production and commercialization rights from Pfizer in 2018. ALK-1 antibody can inhibit tumor blood vessel growth, reduce blood flow and angiogenesis by blocking the ALK-1 receptor pathway, thereby slowing tumor growth and changing the tumor microenvironment. As a potential first-in-class innovative drug in the world, it is expected to be used in the treatment of various solid tumors.Pfizer has conducted two phase I clinical trials on GT90001 in the United States, Italy, South Korea and Japan, which showed good safety and preliminary effectiveness in more than 100 patients with advanced solid tumors. Currently, Kintor Pharmaceutical is conducting phase II clinical trial of GT90001 combined with Nivolumab (PD-1 antibody) for the treatment of advanced liver cancer in Taiwan.

About Kintor Pharmaceutical Limited

Founded in 2009, Kintor Pharmaceuticals aims to become a leading enterprise in the R&D and commercialization of “best-in-class” and “first-in-class” innovative therapies. The Company initially focused on androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively developed a diversified product pipeline that includes small molecule innovative drugs, bio-innovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as PD-L1/TGF-β dual-targeting antibody, AR-Degrader and c-Myc inhibitors that are undergoing preclinical research. Globally, the Company has more than 60 issued patents or under review, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock ticker 9939.HK. Please visit http://www.kintor.com.cn for more information.

Cision View original content:http://www.prnewswire.com/news-releases/stellar-results-from-kintors-gt90001-and-opdivo-combo-therapy-in-the-second-line-treatment-of-advanced-liver-cancer-orr-reached-up-to-40-301190036.html

SOURCE Kintor Pharmaceutical Limited

Posted on

UNO! Mobile Wins 2020 Best of Galaxy Store Award for Best Casual Game

—Mattel163 announced today that UNO! Mobile received the 2020 Best of Galaxy Store Award for Best Casual Game from Samsung.

El Segundo, CA, Dec. 09, 2020 (GLOBE NEWSWIRE) — “We are honored to receive this award from Galaxy Store. Samsung has been an amazing partner in marketing and supporting our games. We’re delighted to be working with such a wonderful partner. We will continue to work hard to delight the fans in our community with outstanding games.” – Amy Huang, CEO of Mattel163 Limited

 

Mattel163, a world class publishing and development studio from Mattel and NetEase is the developer behind hugely popular mobile titles UNO! Mobile and Phase 10: World Tour. We will soon be launching another family favorite Skip-Bo, car racing game Bumper Go, and other exciting titles under development. UNO! Mobile launched globally in 2018 and has since welcomed over 200M players from all around the world. It has collaborated with global entertainment phenomenon BTS, leading toy car brand Hot Wheels, and many more exciting events to come!

“The success of Galaxy Store is determined by the creativity and dedication of the Samsung Developers community,” said Jong Woo, Vice President & Head of Game Ecosystem. “We relaunched Galaxy Store to create a go-to place for mobile gamers that delivers unique benefits and provides users with access to a vast array of content to personalize their Galaxy devices. This year’s winners truly represent the best across all categories.”

UNO! Mobile is available for download on the Galaxy Store, Google Play, and Apple Store and can also be played on Facebook.

###

 

If you would like more information about UNO! Mobile, or anything else happening at Mattel163 Limited, please email Alex Boer at [email protected].

 



Alex Boer
Mattel163
[email protected]

Posted on

SHAREHOLDER ALERT: CLAIMSFILER REMINDS FAF, RTX, TRQ INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

NEW ORLEANS, Dec. 09, 2020 (GLOBE NEWSWIRE) — ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:


Turquoise Hill Resources Ltd. (TRQ


)


Class Period: 7/17/2018 – 7/31/2019
Lead Plaintiff Motion Deadline: December 14, 2020
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-turquoise-hill-resources-ltd-securities-litigation-1


First American Financial Corp. (FAF)


Class Period: 2/17/2017 – 10/22/2020
Lead Plaintiff Motion Deadline: December 24, 2020
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-first-american-financial-corp-securities-litigation


Raytheon Technologies Corporation f/k/a Raytheon Company (RTX, RTN)


Class Period: 2/10/2016 – 10/27/2020
Lead Plaintiff Motion Deadline: December 29, 2020
SECURITIES FRAUD
To learn more, visit https://www.claimsfiler.com/cases/view-raytheon-technologies-corporation-securities-litigation  

If you purchased shares of the above companies and would like to discuss your legal rights and your right to recover for your economic loss, you may, without obligation or cost to you, contact us toll-free (844) 367-9658 or visit the case links above.

If you wish to serve as a Lead Plaintiff in the class action, you must petition the Court on or before the Lead Plaintiff Motion deadline.

About ClaimsFiler

ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.

To learn more about ClaimsFiler, visit www.claimsfiler.com